Genset SA, a biotechnology company, was established in 1989 in Paris, France with Pascal Brandys as its first president. Genset was listed on the NASDAQ and the Paris Bourse (now NYSE Euronext) in 1996. Genset rapidly became the European flagship company in the field of genomics and became the second largest biotechnology company in Europe in 1999 and had subsidiaries in the United States, Japan, Singapore, and Australia. In 1994, Genset started the first large scale program to analyze the regulatory sequences of the human genome and in 1997 also initiated the construction of a map of single nucleotide polymorphisms as a tool to accelerate the discovery of genes associated with diseases. Genset led the pharmaco genomics field and started the first pharmacogenomics research program in the world in collaboration with Abbott Laboratories in 1997. Genset was acquired by Serono of Switzerland in 2002, now part of Merck Serono.
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.